Journal de la dépression et de l'anxiété
Libre accès

Abstrait

Serum Brain-Derived Neurotrophic Factor Level, Plasma 3-Methoxy-4-Hydroxyphenylglycol Level in Major Depressed Patients with Paroxetine Monotherapy

Reiji Yoshimura, Kiyokazu Atake, Hikaru Hori and Asuka Katsuki

Objective: We investigated the relationships among clinical efficacy, brain-derived neurotrophic factor (BDNF), 3-methoxy-4-hydroxyphenylglycol (MHPG), and paroxetine concentration in patients with major depressive disorder (MDD) who treated with paroxetine monotherapy.

Subjects and methods: Forty-nine patients in major depressive disorder diagnosed by Diagnostic and Statistical Manual of Mental Disorders-IV Text Revision (DSM-IV-TR) were enrolled in the study. All patients were treated with paroxetine for 8 weeks at a dose of 40 mg/day. Twenty-eight patients were completed the study. Their depressive symptoms were evaluated with the 17-item Hamilton Rating Scale for Depression (HAMD17). Plasma levels of MHPG and paroxetine were measured by high-performance liquid chromatography, and serum BDNF was measured by Enzyme-Linked Immuno Sorbent Assay (ELISA).

Results: Any correlations were observed between each factor.

Conclusion: Paroxetine concentration was independently in its clinical outcome and alteration of biological parameters.